Despite the safety concerns plaguing Abbott‘s (NYSE:ABT) Absorb device, companies developing bioresorbable scaffolds are not discouraged. This week at the annual Transcatheter Cardiovascular Therapeutics Conference in Denver, a number of companies touted the safety data coming from clinical trials of their products.
Among them were Reva Medical (ASX:RVA) and Biotronik – here’s an overview of that data.
Get the full story at our sister site, Drug Delivery Business News.